Neogenomics INC: management transactions · United States · SEC (Form 4)

About Neogenomics INC

NeoGenomics, Inc. is a U.S.-listed oncology diagnostics company traded on the NASDAQ in the United States. Headquartered in Fort Myers, Florida, the group is focused on cancer genetics testing, pathology support, and precision-medicine solutions for oncologists, pathologists, hospitals, academic centers, and pharmaceutical partners. Its business model combines laboratory testing, advanced molecular diagnostics, and consultative services, making it one of the more specialized names in the oncology diagnostics space. Founded in the early 2000s, NeoGenomics has evolved from a regional laboratory operator into a broader oncology diagnostics platform with a nationwide footprint. In 2024, management simplified the operating structure into a single integrated segment, bringing Clinical Services and Advanced Diagnostics together. That move reflects a clearer commercial strategy and a stronger focus on operating efficiency, cross-selling, and end-to-end cancer testing workflows. The company’s menu includes cytogenetics, histopathology, molecular diagnostics, next-generation sequencing (NGS), biomarker testing, and therapy-selection tools designed to support diagnosis, treatment planning, and disease monitoring. From a competitive standpoint, NeoGenomics operates in a market that is both attractive and highly contested. It competes with large reference laboratories, molecular diagnostics companies, and specialized oncology testing providers. Its competitive edge lies in deep oncology specialization, a broad and clinically relevant test portfolio, medical interpretation capabilities, and a data-driven approach to precision medicine. The company is also notable for its geographic reach: it operates CAP-accredited and CLIA-certified laboratories across several U.S. locations, with an additional laboratory presence in Cambridge, United Kingdom. That footprint supports national service coverage and gives the company flexibility in sample processing and clinical support. Recent developments underscore NeoGenomics’ push toward higher-value, innovation-led growth. In the first quarter of 2026, the company reported 11% year-over-year revenue growth, led by 14% growth in Clinical revenue, and raised its full-year 2026 revenue guidance. Management also highlighted the launch of RaDaR ST, a ctDNA assay for molecular residual disease detection, along with a favorable MolDX coverage decision for PanTracer LBx and the introduction of PanTracer Pro. These initiatives strengthen the company’s oncology precision-testing platform and expand its addressable market in advanced cancer diagnostics. For investors, NeoGenomics is a U.S. NASDAQ-listed healthcare diagnostics company with a focused oncology franchise, improving operating momentum, and a product pipeline aimed at capturing secular growth in molecular testing and precision oncology.